JP2014504865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504865A5 JP2014504865A5 JP2013547842A JP2013547842A JP2014504865A5 JP 2014504865 A5 JP2014504865 A5 JP 2014504865A5 JP 2013547842 A JP2013547842 A JP 2013547842A JP 2013547842 A JP2013547842 A JP 2013547842A JP 2014504865 A5 JP2014504865 A5 JP 2014504865A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- reference nucleic
- binding
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 67
- 150000007523 nucleic acids Chemical class 0.000 claims 67
- 102000039446 nucleic acids Human genes 0.000 claims 67
- 125000003729 nucleotide group Chemical group 0.000 claims 36
- 239000002773 nucleotide Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 18
- 108091028664 Ribonucleotide Proteins 0.000 claims 5
- 239000005547 deoxyribonucleotide Substances 0.000 claims 5
- 239000002336 ribonucleotide Substances 0.000 claims 5
- 125000002652 ribonucleotide group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11000117.9 | 2011-01-10 | ||
| EP11000117 | 2011-01-10 | ||
| EPPCT/EP2011/002068 | 2011-04-21 | ||
| PCT/EP2011/002068 WO2011131371A1 (en) | 2010-04-21 | 2011-04-21 | Lipid binding nucleic acids |
| EP11008467.0 | 2011-10-21 | ||
| EP11008467 | 2011-10-21 | ||
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075557A Division JP2017148055A (ja) | 2011-01-10 | 2017-04-05 | 標的分子との結合親和性を有する核酸分子およびその生成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014504865A JP2014504865A (ja) | 2014-02-27 |
| JP2014504865A5 true JP2014504865A5 (enExample) | 2015-03-05 |
Family
ID=45464586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547842A Pending JP2014504865A (ja) | 2011-01-10 | 2012-01-10 | 標的分子との結合親和性を有する核酸分子およびその生成方法 |
| JP2017075557A Pending JP2017148055A (ja) | 2011-01-10 | 2017-04-05 | 標的分子との結合親和性を有する核酸分子およびその生成方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075557A Pending JP2017148055A (ja) | 2011-01-10 | 2017-04-05 | 標的分子との結合親和性を有する核酸分子およびその生成方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9976145B2 (enExample) |
| EP (1) | EP2663640B1 (enExample) |
| JP (2) | JP2014504865A (enExample) |
| KR (2) | KR20140026357A (enExample) |
| CN (1) | CN103339258A (enExample) |
| AU (1) | AU2012206750A1 (enExample) |
| CA (1) | CA2824073A1 (enExample) |
| WO (1) | WO2012095303A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012325233A1 (en) * | 2011-10-21 | 2014-04-24 | Noxxon Pharma Ag | Glucagon binding nucleic acids |
| MX2014008456A (es) * | 2012-01-10 | 2014-11-25 | Noxxon Pharma Ag | Acidos nucleicos que enlazan especificamente a cgrp. |
| PL2802660T3 (pl) * | 2012-01-10 | 2020-07-27 | Aptarion Biotech Ag | Nowe kwasy nukleinowe wiążące c5a |
| US11172873B2 (en) | 2018-05-17 | 2021-11-16 | The Procter & Gamble Company | Systems and methods for hair analysis |
| MX2020012225A (es) | 2018-05-17 | 2021-01-29 | Procter & Gamble | Sistemas y metodos para el analisis de la cobertura del cabello. |
| US11384357B2 (en) | 2018-06-29 | 2022-07-12 | The Procter And Gamble Company | Aptamers for personal care applications |
| WO2020214784A1 (en) | 2019-04-16 | 2020-10-22 | The Procter & Gamble Company | Aptamers for odor control applications |
| US12039732B2 (en) | 2021-04-14 | 2024-07-16 | The Procter & Gamble Company | Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications |
| EP4306640A1 (en) | 2022-06-21 | 2024-01-17 | TME Pharma AG | Method for treating a tumor in a subject |
| CA3257623A1 (en) | 2022-06-21 | 2023-12-28 | TME Pharma AG | METHODS OF TREATING A TUMOR IN A SUBJECT |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| EP0533838B1 (en) | 1990-06-11 | 1997-12-03 | NeXstar Pharmaceuticals, Inc. | Nucleic acid ligands |
| DE59708838D1 (de) | 1996-08-30 | 2003-01-09 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| ATE452655T1 (de) | 2001-06-10 | 2010-01-15 | Noxxon Pharma Ag | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung |
| ATE469164T1 (de) | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| ATE441706T1 (de) | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| RU2394041C2 (ru) | 2003-04-13 | 2010-07-10 | Энзон Фармасьютикалз, Инк. | Полимерные олигонуклеотидные пролекарства |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| CN1894407A (zh) * | 2003-11-10 | 2007-01-10 | 诺松制药股份公司 | 特异性结合生物活性生长素释放肽的核酸 |
| EP1713509A2 (de) | 2004-02-09 | 2006-10-25 | Noxxon Pharma AG | Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
| WO2006052790A2 (en) | 2004-11-05 | 2006-05-18 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| US20090075342A1 (en) | 2005-04-26 | 2009-03-19 | Sharon Cload | Metabolic profile directed aptamer medicinal chemistry |
| US20120101267A1 (en) | 2005-10-07 | 2012-04-26 | Alison Velyian Todd | Multicomponent nucleic acid enzymes with cleavage, ligase or other activity and methods for their use |
| ATE516369T1 (de) | 2005-10-07 | 2011-07-15 | Johnson & Johnson Res Pty Ltd | Nukleinsäure-enzyme mit mehreren bestandteilen und verfahren zu deren verwendung |
| AU2007296054B2 (en) | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| KR101583834B1 (ko) | 2007-04-05 | 2016-01-19 | 존슨 앤드 존슨 리서치 피티와이 리미티드 | 핵산 효소 및 복합체 및 이의 사용 방법 |
| CA2732142A1 (en) * | 2008-07-28 | 2010-02-04 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
| EP2561079A1 (en) | 2010-04-21 | 2013-02-27 | Noxxon Pharma AG | Lipid binding nucleic acids |
-
2012
- 2012-01-10 CA CA2824073A patent/CA2824073A1/en not_active Abandoned
- 2012-01-10 KR KR1020137017897A patent/KR20140026357A/ko not_active Ceased
- 2012-01-10 US US13/978,804 patent/US9976145B2/en active Active
- 2012-01-10 EP EP12700093.3A patent/EP2663640B1/en active Active
- 2012-01-10 JP JP2013547842A patent/JP2014504865A/ja active Pending
- 2012-01-10 CN CN201280007720XA patent/CN103339258A/zh active Pending
- 2012-01-10 WO PCT/EP2012/000089 patent/WO2012095303A1/en not_active Ceased
- 2012-01-10 KR KR1020197016125A patent/KR102080142B1/ko active Active
- 2012-01-10 AU AU2012206750A patent/AU2012206750A1/en not_active Abandoned
-
2017
- 2017-04-05 JP JP2017075557A patent/JP2017148055A/ja active Pending
-
2018
- 2018-05-21 US US15/985,626 patent/US20190367921A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504865A5 (enExample) | ||
| JP2017536119A5 (enExample) | ||
| Pu et al. | Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment | |
| JP2013511990A5 (enExample) | ||
| Cox et al. | Structural studies on the authentic mumps virus nucleocapsid showing uncoiling by the phosphoprotein | |
| JP2013516190A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2014513954A5 (enExample) | ||
| JP2016530294A5 (enExample) | ||
| JP2015517806A5 (enExample) | ||
| JP2008283975A5 (enExample) | ||
| JP2017070307A5 (enExample) | ||
| WO2007090071A3 (en) | 6-modified bicyclic nucleic acid analogs | |
| JP2008245635A5 (enExample) | ||
| JP2009524696A5 (enExample) | ||
| JP2017079759A5 (enExample) | ||
| JP2017536366A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2008534695A5 (enExample) | ||
| JP2009017881A5 (enExample) | ||
| JP2015513535A5 (enExample) | ||
| JP2014533241A5 (enExample) | ||
| JP2009543567A5 (enExample) | ||
| JP2014516027A5 (enExample) | ||
| JP2009544281A5 (enExample) |